The recent approvals of both teriflunomide (Aubagio®) and alemtuzumab (Lemtrada®) have meant that substantially more can now be offered to patients with multiple sclerosis (MS). In clinical trials, teriflunomide has shown consistent efficacy across patients with early disease (TOPIC study, n=618) and in patients with relapsing forms of MS (TEMSO, n=1,088 and TOWER studies n=1,169). Teriflunomide 14 mg/day showed consistent efficacy in patients with varying levels of disease activity and is the only approved oral MS therapy that significantly delayed disability progression in two phase III clinical trials. The safety profile of teriflunomide now extends to 12 years and the data support its use as a platform agent in patients with relapsing MS (RMS). In other phase II and III clinical trials (CAMMS223, n=334, CARE-MS 1, n=581 and CARE-MS 2, n=840), alemtuzumab has demonstrated superior efficacy (clinical and magnetic resonance imaging [MRI]) than high-dose subcutaneous (s.c.) interferon beta (IFNβ-1a). It has also shown improvement in pre-existing disability compared with IFNβ-1a s.c. and sustained efficacy over 3–4 years despite no further therapy after the second administration in the majority of the patients. Alemtuzumab has a consistent, well-characterised safety profile, so adverse events can be identified and managed using a comprehensive safety monitoring and education programme. Both teriflunomide and alemtuzumab therefore have favourable benefit– risk profiles in patients with early and/or active RMS. Their efficacies constitute real advances in MS treatment and in regular clinical use are likely to effectively control disease and improve outcomes for many MS patients.
Teriflunomide, alemtuzumab, efficacy, safety, multiple sclerosis, patient selection, treatment administration, treatment timing
Bart Van Wijmeersch has received research and travel grants and honoraria for multiple sclerosis expert advice and speakers fees from Bayer-Schering,
Biogen, Genzyme-Sanofi, Merck-Serono, Novartis and Teva. Celia Oreja-Guevara has received advisory board and consulting honoraria from Bayer, Biogen, Genzyme-Sanofi,
Merck-Serono, Novartis and Teva. Ron Milo has received research grants, travel funding, speaker’s honoraria or consultation fees from Bayer-Schering, Biogen Idec,
Genzyme, Medison Pharma, Neopharm, Novartis, Merck-Serono and Teva.
Editorial assistance was provided by James Gilbart at Touch Medical Media, London and funded by Genzyme. This article reports the proceedings of
a sponsored satellite symposium and as such has not been subject to the journal’s usual peer-review process.
July 01, 2015 Accepted
August 26, 2015
Ron Milo, Department of Neurology, Barzilai Medical Center, Ashkelon 78278, Israel E: email@example.com
This article was supported by Genzyme (a Sanofi company).
This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation
and reproduction provided the original author(s) and source are given appropriate credit.
Despite the availability of disease-modifying therapies (DMTs) in multiple sclerosis (MS) for over 2 decades, substantial unmet treatment needs have remained. From the patient perspective, there is a need for better tolerability, quality of life (QoL) benefits and customised treatment approaches that are based on disease prognosis and individual patient needs and risk– benefit ratio. From the healthcare provider perspective, there is a need for treatment approaches that address individual prognosis, optimised treatment outcomes in an increasingly complex treatment landscape and ability to achieve new treatment goals.1–11 The recent approvals of the oral treatment teriflunomide (Aubagio®) and the intravenous (IV) monoclonal antibody (mAb) treatment alemtuzumab (Lemtrada®) in MS have markedly changed the options available to neurologists and their ability to achieve these goals. This review considers how teriflunomide and alemtuzumab can fit into current and future treatment approaches to MS as discussed at a satellite symposium and a plenary session that were convened at the 9th Controversies in Neurology meeting at Budapest, Hungary, in March 2015.
Teriflunomide – For Whom, When, How?
Teriflunomide is a once-daily oral therapy that was approved for the treatment of relapsing forms of MS by the US Food and Drug Administration (FDA) in September 2012 and by the EU Commission in Europe in August 2013. The mode of action of teriflunomide in MS is not fully understood but it is known to selectively and reversibly inhibit dihydroorotate reductase, a key mitochondrial enzyme involved in de novo pyrimidine synthesis, which is required for the proliferation of activated lymphocytes. This results in fewer B and T cells crossing the blood–brain barrier. Teriflunomide also reduces the ability of activated B and T cells to participate in the damaging immune attack on the central nervous system and has other modes of action.12 These actions are quite specific and preserve adaptive immunity to infectious pathogens, which is an advantage over some other immunomodulating agents used in MS.13,14 Teriflunomide is not cytotoxic and does not deplete lymphocytes, so can be described as an immunomodulatory agent.
1. Merck-Serono Europe Ltd, Summary of product
characteristics - Rebif solution for injection in cartridges,
2014. Available at: www.medicines.org.uk/emc/
medicine/22368 (accessed 9 April 2015).
2. Biogen Idec Ltd, Summary of product characterstics -
Tecfidera 240mg gastro-resistant hard capsules, 2014.
Available at: www.medicines.org.uk/emc/medicine/28592
(accessed 9 April 2015).
3. Derfuss T, Personalized medicine in multiple sclerosis: hope
or reality?, BMC Med, 2012;10:116.
4. Devonshire V, Lapierre Y, Macdonell R, et al., The Global
Adherence Project (GAP): a multicenter observational study
on adherence to disease-modifying therapies in patients
with relapsing-remitting multiple sclerosis, Eur J Neurol,
5. Fox EJ, Rhoades RW, New treatments and treatment goals for
patients with relapsing-remitting multiple sclerosis, Curr Opin
Neurol, 2012; Suppl. 25:S11–9.
6. Johnson FR, Van Houtven G, Ozdemir S, et al., Multiple sclerosis
patients’ benefit-risk preferences: serious adverse event risks
versus treatment efficacy, J Neurol, 2009;256:554–62.
7. Lobentanz IS, Asenbaum S, Vass K, et al., Factors influencing
quality of life in multiple sclerosis patients: disability,
depressive mood, fatigue and sleep quality, Acta Neurol
8. Lorefice L, Mura G, Coni G, et al., What do multiple sclerosis
patients and their caregivers perceive as unmet needs?,
BMC Neurol, 2013;13:177.
9. Miller A, Avidan N, Tzunz-Henig N, et al., Translation towards
personalized medicine in Multiple Sclerosis, J Neurol Sci,
10. Patti F, Optimizing the benefit of multiple sclerosis therapy:
the importance of treatment adherence, Patient Prefer
11. Tanasescu R, Ionete C, Chou IJ, et al., Advances in the
treatment of relapsing-remitting multiple sclerosis,
Biomed J, 2014;37:41–9.
12. Haghikia A, Gold R, Multiple sclerosis: TOWER confirms
the efficacy of oral teriflunomide in MS, Nat Rev Neurol,
13. Bayas A, Maurer M, Teriflunomide for the treatment of
relapsing-remitting multiple sclerosis: patient preference and
adherence, Patient Prefer Adherence, 2015;9:265–4.
14. Oh J, O’Connor PW, Teriflunomide in the treatment of multiple
sclerosis: current evidence and future prospects, Ther Adv
Neurol Disord, 2014;7:239–52.
15. Confavreux C, Li DK, Freedman MS, et al., Long-term followup
of a phase 2 study of oral teriflunomide in relapsing
multiple sclerosis: safety and efficacy results up to 8.5 years,
Mult Scler, 2012;18:1278–89.
16. O’Connor P, Wolinsky JS, Confavreux C, et al., Randomized
trial of oral teriflunomide for relapsing multiple sclerosis,
N Engl J Med, 2011;365:1293–303.
17. Confavreux C, O’Connor P, Comi G, et al., Oral teriflunomide
for patients with relapsing multiple sclerosis (TOWER): a
randomised, double-blind, placebo-controlled, phase 3 trial,
Lancet Neurol, 2014;13:247–56.
18. Vermersch P, Czlonkowska A, Grimaldi LM, et al.,
Teriflunomide versus subcutaneous interferon beta-1a in
patients with relapsing multiple sclerosis: a randomised,
controlled phase 3 trial, Mult Scler, 2014;20:705–16.
19. Miller AE, Wolinsky JS, Kappos L, et al., Oral teriflunomide for
patients with a first clinical episode suggestive of multiple
sclerosis (TOPIC): a randomised, double-blind, placebocontrolled,
phase 3 trial, Lancet Neurol, 2014;13:977–86.
20. Bar-Or A, Freedman MS, Kremenchutzky M, et al., Teriflunomide
effect on immune response to influenza vaccine in patients
with multiple sclerosis, Neurology, 2013;81:552–8.
21. Freedman F, Confavreux C, Olsson T, et al., 2013, Teriflunomide
Efficacy and Safety Analyses: Results From TEMSO and TOWER
(P5), Americas Commitee on treatment and Research in
Multiple Sclerosis (ACTRIMS) Orlando, Florida, US.
22. Wolinsky JS, Narayana PA, Nelson F, et al., Magnetic
resonance imaging outcomes from a phase III trial of
teriflunomide, Mult Scler, 2013;19:1310–9.
23. Bar-Or A, 2013, Immune response to neoantigen and
recall antigens in healthy subjects receiving teriflunomide
P622, 29th Congress of the European Committee on
Treatment and research in Multiple Sclerosis (ECTRIMS),
24. Menguy-Vacheron F, Varona R, Posevitz-Fejfar A, et al., 2013,
Exploring the impact of teriflunomide on immune cells in
patients with relapsing multiple sclerosis: design of the
Teri-Dynamic study, 23rd Meeting of the European Society of
Neurology, Barcelona, Spain.
25. Vollmer TL, Stalla-Bourdillon A, Robinson M, 2013,
Teriflunomide in Routine Clinical Practice: Design of the Teri-
PRO Study DX58, 5th Cooperative Meeting of the Consortium
of Multiple Sclerosis Centers (CMSC), Orlando, Florida, US.
26. Chitnis T, Banwell B, Arnold DL, et al., 2014, Study Design
of a Phase 3 Trial Evaluating Teriflunomide in Children and
Adolescents with Relapsing Multiple Sclerosis, Cooperative
Meeting of the Consortium of Multiple Sclerosis Centers,
Dallas, Texas, US.
27. Kappos L, Comi G, Freedman MS, et al., 2013, Pooled efficacy
data from two phase 3 placebo-controlled trials of oral, oncedaily
teriflunomide P618, 29th Congress of the European
Ciommittee for Treatment and Research in Multiple Sclerosis,
28. Freedman MS, Dukovic D, Benamor M, et al., 2014, Consistent
treatment effect of teriflunomide in subgroups based on pretrial
therapy: pooled analyses of TEMSO and TOWER (DX47),
Annual Meeting of the Consortium of Multiple Sclerosis
Centers (CMSC), Dallas, Texas, USA.
29. Macdonell R, 2013, Teriflunomide reduces relapse-related
sequelae, severe relapses, hospitalisations and corticosteroid
use: pooled data from the phase 3 TEMSO and TOWER studies
(P1095). 29th Congress of the European Committee for
Treatments and Research in Multiple Sclerosis, Copenhagen,
30. Marurer M, 2013, Impact of severe relapses on disability,
fatigue and healthrelated quality of life outcomes: a pooled
dataset of the phase 3 TEMSO and TOWER studies, 29th
Congress of the European Committee on Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark.
31. Freedman MS, Comi G, Kappos L, et al., 2013, Long-term safety
and efficacy of teriflunomide in patients with relapsing forms
of multiple sclerosis in the TEMSO extension trial (P544),
29th Congress of the European Committe for Treatment and
Research in Multiple Sclerosis Copenhagen, Denmark.
32. Leist T, Hunter SF, Kantor D, et al., Novel therapeutics in
multiple sclerosis management: clinical applications,
Am J Med, 2014;127:S2.
33. Singer B, Comi G, Miller A, et al., 2013, Frequency of infections
during treatment with teriflunomide: pooled data from three
placebo-controlled teriflunomide studies (P01.171), American
Academy of Neurology Annual Meeting, San Diego, CA, USA.
34. sanofi-aventis groupe, Summary of product characteristics -
AUBAGIO 14 mg film-coated tablets, 2014. Available at: http://
www.medicines.org.uk/emc/medicine/28533 (accessed 6
35. Atkinson MJ, Sinha A, Hass SL, et al., Validation of a general
measure of treatment satisfaction, the Treatment Satisfaction
Questionnaire for Medication (TSQM), using a national panel
study of chronic disease, Health Qual Life Outcomes, 2004;2:12.
36. Vermersch P, Czlonkowska A, Grimaldi L, et al., 2012,
Evaluation of patient satisfaction from the TENERE study: a
comparison of teriflunomide and subcutaneous interferon
beta-1a in patients with relapsing multiple sclerosis, 22nd
Meeting of the European Neurologiocal Society, Prague,
37. Hu Y, Turner MJ, Shields J, et al., Investigation of the
mechanism of action of alemtuzumab in a human CD52
transgenic mouse model, Immunology, 2009;128:260–70.
38. Coles AJ, Twyman CL, Arnold DL, et al., Alemtuzumab for
patients with relapsing multiple sclerosis after diseasemodifying
therapy: a randomised controlled phase 3 trial,
39. Cox AL, Thompson SA, Jones JL, et al., Lymphocyte
homeostasis following therapeutic lymphocyte depletion in
multiple sclerosis, Eur J Immunol, 2005;35:3332–42.
40. Hartung HP, Arnold DL, Cohen JA, 2012, Lymphocyte subset
dynamics following alemtuzumab treatment in the CARE-MS
1 study (P 935), 28th Congress of the European Committee
for Treatment and Research in Multiple Sclerosis (ECTRIMS),
41. Turner MJ, Lamorte MJ, Chretien N, et al., Immune status
following alemtuzumab treatment in human CD52 transgenic
mice, J Neuroimmunol, 2013;261:29–36.
42. Cohen JA, Coles AJ, Arnold DL, et al., Alemtuzumab versus
interferon beta 1a as first-line treatment for patients
with relapsing-remitting multiple sclerosis: a randomised
controlled phase 3 trial, Lancet, 2012;380:1819–28.
43. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et
al., Alemtuzumab vs. interferon beta-1a in early multiple
sclerosis, N Engl J Med, 2008;359:1786–801.
44. Arroyo R, Arnold DL, Cohen J, et al., 2013, Alemtuzumab
improves quality of life compared to SC IFNβ-1a in CARE-MS
II (P531), 23rd Meeting of the European Neurological Society,
Barcelona, Spain. Available at: www.congrex-switzerland.
(accessed 6 July 2015).
45. Gupta A, Arnold D, Cohen J, et al., 2012, Alemtuzumab
improves quality of life compared to SC IFNβ-1A in
CARE-MS I, Annukla meeting of the Consortium of
Multiple Sclerosis Centers, San Diego, CA, US.
46. Coles AJ, 2014, Efficacy and safety of alemtuzumab in
treatment naive patients with relapsing-remitting MS: fouryear
follow-up of the CARE-MS I study (P090) Joint Meeting
of the American Committe for Treatment and Research in
Multiple Sclerosis and European Committe for Treatment and
Research in Multiple Sclerosis, Boston, Massachusetts, US.
47. Hartung HP, Arnold DL, Cohen JA, 2014, Efficacy and safety
of alemtuzumab in patients with relapsing-remitting MS who
relapsed on prior therapy: four-year follow-up of the CAREMS
II study (P043), 20 1 (Suppl), Joint Meeting of the American
Committe for Treatment and Research in Multiple Sclerosis
and European Committe for Treatment and Research in
Multiple Sclerosis, Boston, MA, US.
48. Arnold DL, 2014, Alemtuzumab improves brain MRI outcomes
in patients with active relapsing-remitting multiple sclerosis:
three-year followup of the CARE-MS studies (P008), 66th
Annual Meeting of the Amerian Academy of Neurology,
Philadelphia, PA, US.
49. Arnold D, Brinar V, Cohen J, 2012, Effect of alemtuzumab vs
Rebif® on brain MRI measurements: results of CARE-MS I,
a phase 3 study (S11.006), Annual Meeting of the American
Academy of Neurology, New Orleans, LA, USA.
50. Arnold DL, 2012, Effect of alemtuzumab vs Rebif® on
brain MRI measurements (P877), European Committee on
Treatment and Research in Multiple Sclerosis, Lyon, France.
51. Coles AJ, Cox A, Le Page E, et al., The window of therapeutic
opportunity in multiple sclerosis: evidence from monoclonal
antibody therapy, J Neurol, 2006;253:98–108.
52. Coles AJ, Wing MG, Molyneux P, et al., Monoclonal antibody
treatment exposes three mechanisms underlying the
clinical course of multiple sclerosis, Ann Neurol,
53. Genzyme Therapeutics Ltd, Summary of product
characteristics - LEMTRADA 12 mg concentrate for solution
for infusion, 2013. Available at: www.medicines.org.uk/emc/
medicine/28917 (accessed 14 April 2015).
54. Havrdova E, 2013, Infection risk with alemtuzumab in patients
with relapsing remitting multiple sclerosis: pooled results
from the CARE-MS I and CARE-MS II trials, 29th Congress
of the European Committee on treatment and Research in
Multiple Sclerosis, Copenhagen, Denmark.
55. Twyman C, Oyuela P, Palmer J, et al., Thyroid autoimmune
adverse events in patients treated with alemtuzumab for
relapsing-remitting multiple sclerosis: four-year follow-up of
the CARE-MS studies, Neurology, 2014;82 Supplement P2.199.
56. Cuker A, Stasi R, Palmer J, et al., Successful detection and
management of immune thrombocytopenia in alemtuzumabtreated
patients with active relapsing-remitting multiple
sclerosis, Neurology, 2014;82 10 Supplement:1526
57. Babij R, Perumal JS, Comparative efficacy of alemtuzumab
and established treatment in the management of multiple
sclerosis, Neuropsychiatr Dis Treat, 2015;11:1221–9.
58. McDonald WI, Compston A, Edan G, et al., Recommended
diagnostic criteria for multiple sclerosis: guidelines from the
International Panel on the diagnosis of multiple sclerosis,
Ann Neurol, 2001;50:121–7.
59. Polman CH, Reingold SC, Edan G, et al., Diagnostic criteria for
multiple sclerosis: 2005 revisions to the “McDonald Criteria”,
Ann Neurol, 2005;58:840–6.
60. Wynn D, Arnold DL, Coles AJ, Detection, incidence, and
management of glomerulonephritis in the alemtuzumab
clinical development program (P597) 29th Congress of the
European Committee for Research and Treatment in Multiple
Sclerosis (ECTRIMS), Copenhagen, Denmark.
61. Coles AJ, Fox E, Vladic A, et al., Alemtuzumab more effective
than interferon beta-1a at 5-year follow-up of CAMMS223
clinical trial, Neurology, 2012;78:1069–78.
62. Cohen J, Twyman C, Arnold D, et al., 2012, Efficacy and safety
results from comparison of alemtuzumab and Rebif® efficacy
in multiple sclerosis II (CARE-MS II): A phase 3 study in
relapsing-remitting multiple sclerosis patients whorelapsed
on Prior therapy (S01.004), Annual Meeting of the American
Academy of Neurology, New Orleans, LA, US.
Teriflunomide, alemtuzumab, efficacy, safety, multiple sclerosis, patient selection, treatment administration, treatment timing